- Codis has received a growth investment from 1315 Capital, alongside existing shareholders BroadOak Capital Partners and Research Corporation Technologies (RCT).
- The funding will support the expansion of Codis’s commercial manufacturing capacity at its Haverhill, UK facility.
Codis, a contract development and manufacturing organisation (CDMO) specialising in commercial spray drying, amorphous solid dispersions (ASD), particle engineering, and finished-dose manufacturing, has announced a growth investment from 1315 Capital. Existing shareholders BroadOak Capital Partners and Research Corporation Technologies (RCT) also participated in the funding round.
The investment will accelerate the expansion of Codis’s Haverhill, UK facility, enhancing the company’s ability to support customers scaling to commercial supply. Codis operates more than 400,000 square feet of cGMP facilities across St. Louis, MO; Seymour, IN; and Haverhill, UK, offering large-scale spray-drying and related technologies for pharmaceutical, consumer health, nutraceutical, and OTC markets.
Codis’s platform has an annual production capacity exceeding 5,000 metric tons of spray-dried product, representing one of the largest commercial spray-drying operations worldwide. The expansion in Haverhill is intended to strengthen the company’s global network and reduce time to supply for customers.
“We’re pleased to welcome 1315 Capital alongside RCT and BroadOak; this investment enables us to expand capacity in Haverhill to better support customers scaling to commercial supply.”
Nicolas Fortin, Chief Executive Officer of Codis
Matthew Reber, Partner at 1315 Capital, added, “The pharmaceutical industry increasingly needs spray-drying expertise in order to produce amorphous solid dispersions, drug substances, and functional excipients. We’re proud to partner with Codis as the company expands its commercial manufacturing offerings in these markets.”
